Calvin Brown, MD
Ophthalmology · Olive Branch, MSNPI 1578761011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,540 of the $15,197 with a category attached, or 62.8%. Apellis Pharmaceuticals, Inc. accounts for 60.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $9,801 and has fallen 92.5% since, to $731 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $80.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$9K
- Alimera Sciences, Inc.$2K
- Genentech USA, Inc.$802
- AbbVie$644
- Regeneron Healthcare Solutions, Inc.$424
- Mallinckrodt Hospital Products Inc.$383
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$9,54063%
- Travel & lodging$1021%
- Food & beverage$5,22434%
- Education$1001%
- Gifts$190%
- Entertainment$2121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 27 | $9,213 |
| Alimera Sciences, Inc. | 21 | $2,078 |
| Genentech USA, Inc. | 26 | $802 |
| AbbVie(2 entities) | 40 | $644 |
| Regeneron Healthcare Solutions, Inc. | 15 | $424 |
| Mallinckrodt Hospital Products Inc. | 12 | $383 |
| Eyepoint US, Inc. | 6 | $329 |
| Novartis | 10 | $258 |
| Optos, Inc. | 4 | $212 |
| Biogen | 6 | $179 |
| Astellas Pharma US Inc | 7 | $151 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $115 |
| Notal Vision, Inc. | 1 | $89 |
| Dutch Ophthalmic, USA | 1 | $83 |
| Novo Nordisk | 1 | $49 |
| Coherus Oncology, Inc. | 2 | $48 |
| Bausch & Lomb Americas Inc. | 2 | $33 |
| Spark Therapeutics, Inc. | 2 | $31 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Harrow Eye, LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,197 in reported general payments places this provider in the 90th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 11 | $15,492 |
| Restasis MultidoseCyclosporine | 17 | $10,560 |
| RestasisCyclosporine | 12 | $8,675 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,478 |
| Prednisolone Acetate | 96 | $4,443 |
| Ketorolac Tromethamine | 63 | $2,383 |
| MoxifloxacinMoxifloxacin Hcl | 44 | $926 |
| Latanoprost | 63 | $581 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose, Restasis, Combigan | $644 | $24,71341 claims |
| Bausch & Lomb Americas Inc.Xiidra | $33 | $15,49211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Olive Branch
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- William AshfordMadison$13K
- Jaime JimenezHattiesburg$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.